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ABSTRACT
Background: Paraneoplastic neurological syndromes
(PNS) are indirect remote effects of cancer on the
nervous system, often associated with the presence of
specific serum antibodies. The most recently described
PNS defining reactivity is anti-Ma/anti-Ta. Here we
present 22 newly diagnosed patients with anti-Ma or anti-
Ta reactivity, refine the associated clinical picture and
review all published patients to date.
Patients and methods: Patients were identified by
testing for PNMA1 and PNMA2 antibodies by western
blotting and indirect immunofluorescence. Clinical data
were obtained either by referral of the patient or from the
referring physicians.
Results: Analysis of 22 new patients (14 anti-Ma, eight
anti-Ta) confirmed that anti-Ta are usually found in young
men with limbic encephalitis and testicular germ cell
tumours who stabilise neurologically with long term
survival after tumour treatment. Patients with anti-Ma
were of either sex, middle-aged, presented with a range
of tumours and neurological symptoms and had a limited
response to treatment. Furthermore, we expanded the
range of associated clinical features: (1) the peripheral
nervous system may be involved; (2) an overlap with anti-
Hu is possible; and (3) testicular tumour manifestation
can be extragonadal or detectable only at orchiectomy.
Conclusion: Refining and expanding the range of anti-
Ma/anti-Ta associated neurological presentations and
tumours clearly demonstrated that the distinction
between anti-Ma and anti-Ta associated PNS is of high
clinical relevance.
Paraneoplastic neurological syndromes (PNS) are
indirect remote effects of cancer on the nervous
system.1 2 A positive diagnosis of PNS has become
possible in many cases by identification of highly
specific antibodies in patients’ sera,1 2 and new
diagnostic criteria have been defined.3 Six antibody
reactivities are widely recognised and, if present,
indicate a ‘‘definite’’ PNS.3 Therefore, accurate
antibody testing and description of the associated
clinical syndromes is of high clinical relevance.
In reference to the consensus paper by Graus et
al in 2004,3 anti-Ma/anti-Ta reactivity is the most
recently described PNS defining antibody of the six
specific antibodies described, which define a
neurological syndrome as definite.3–5 Anti-Ta sera
recognise an onconeuronal protein called PNMA2,
and anti-Ma sera recognise PNMA2 and another
protein, PNMA1.4–7 To date, there have been
reports on approximately 50 patients with anti-
Ma or anti-Ta reactivity of whom enough
information is given in the papers to differentiate
12 patients with anti-Ma (reacting with PNMA1
and PNMA2) and 28 patients with anti-Ta (reacting
with PNMA2 only).4–17 Here we describe a further 22
patients with anti-Ma or anti-Ta associated PNS and
comprehensively review all of the cases that have
been reported in the literature.4–17
PATIENTS AND METHODS
Patients were identified in serial routine diagnostic
testing for antineuronal antibodies in Munich and
Oxford between December 1999 and March 2005.
In Munich, sera were tested using western blot
analysis with semi-purified recombinant human
PNMA1 and PNMA2 protein, as described pre-
viously.4 5 Patients’ sera, in parallel with normal
control sera, were diluted 1:500, 1:2000 and 1:5000
in blocking buffer. As secondary antibodies, goat
anti-rabbit IgG-HRP (Santa Cruz, California, USA)
and anti-human IgG peroxidase conjugate (Sigma-
Aldrich, Steinheim, Germany) were used. Antibody
binding was detected using enhanced chemilumine-
scent detection reagents18 (Amersham Biosciences,
New Jersey, USA). In addition, indirect immuno-
fluorescence assays on monkey cerebellum/cere-
brum and on mouse stomach slides were
performed according to the manufacturer’s instruc-
tions (The Binding Site Ltd, Birmingham, UK). In
Oxford, sera were first screened by indirect
immunohistochemistry, as described previously,4 5
and sera with reactivity characteristic of anti-Ma/
Ta were retested and confirmed by binding on
western blots in Munich.
For clinical information, when possible patients
were referred to the Munich centre and attended
our outpatient or inpatient department (6/22
personally seen by LAH and RV). In other cases,
and in Oxford, clinical data were obtained from the
referring physicians, and the clinical management
discussed with them. Patient No 17 has been
reported previously.14 Clinical outcome was rated
according to the modified Rankin Scale.
For review of all published cases, we performed a
Medline database search using the search keys
‘‘Ma, Ta, Ma1, Ma2, paraneoplastic, paraneoplastic
neurological syndromes and limbic encephalitis’’.
Furthermore, we included related links and refer-
ences of the respective articles.
For statistical analysis, comparison of age
distribution (Ma vs Ta positive patients) was done
by the Mann–Whitney rank sum test. Frequencies
of categorical data were analysed by Fisher exact
tests. Data were analysed in an explorative way
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without adjustment for multiple testing. All calculations were
done using SigmaStat V 3.0.1 (SPSS GmbH Software, Munich,
Germany).
RESULTS
Patients are discussed below in relation to their antibody
positivity. Six individual cases are described in detail in the
appendix (available online). All patients fitted the criteria for
definite paraneoplastic syndromes, as defined by Graus and
colleagues.3
Anti-Ma positive patients
Fourteen anti-Ma (reacting with both PNMA1 and PNMA2)
patients were identified (eight females, six males). The patients
are described in table 1 and compared with the anti-Ta positive
patients in table 2.
Most patients had or developed symptoms of limbic encephalitis
(10/14), brainstem or cerebellar encephalitis (8/14), polyneuro-
pathy (2/14), extrapyramidal involvement (1/14) or a combination
thereof (table 1). Neuroimaging showed abnormalities in all 13
patients in whom cerebral MRI was performed (atrophic changes
7/13, localised signal changes 6/13, of those three with gadolinium
enhancement). Two examples are given in figs 1 and 2. CSF
revealed abnormal results in 11/13 patients (in one case, no lumber
puncture was performed), with elevated protein (9/11), pleocy-
tosis (5/11) and positive oligoclonal bands (3/11).
A brain biopsy was performed in four cases. In patient No 2, a
biopsy of a left-sided mesial–temporal lesion showed diffuse
parenchymal and perivascular inflammatory lymphocytic infil-
trates predominantly of T cells (CD3 and CD8), but also of B
cells (CD20 and CD79a) and a distinct reactive astrogliosis (see
fig 3). Molecular genetic studies supported an inflammatory
condition with a polyclonal pattern of the IgH rearrangements.
In patient No 7, a biopsy of the right-sided mesial–basal
temporal lobe showed a subacute encephalitic picture with
lymphocytic and monocytic perivascular cuffs, phagocytosis of
nerve cells, extensive proliferation of microglia and reactive
astrocytosis. In patient No 8, a brainstem biopsy revealed an
inflammatory process with a predominant CD3 and CD68
positive infiltrate, extensive axonal degeneration and reactive
astrocytosis.
Associated tumours
A tumour was histologically identified in nine patients (9/14,
64%). These included lung, gastrointestinal tract, non-Hodgkin
lymphoma, breast, renal and melanoma with mediastinal
lymph nodes. Among those without an identified tumour,
patient No 7 had a history of a non-Hodgkin’s disease (mucosa
associated lymphatic tissue lymphoma in the terminal ileum
14 years ago) with [18F]fluorodeoxyglucose positron emission
tomography (FDG-PET) investigation showing hypermetabo-
lism in the area of the former tumour. Colonoscopy and CT of
the abdomen did not detect any signs of tumour recurrence at
the time of the diagnostic procedures. The patient deteriorated
rapidly with additional signs of hypothalamic involve-
ment (severe hyponatraemia and hypothermia) and died of
Table 2 Clinical features of eight patients with anti-Ta associated paraneoplastic syndrome
Patient
No
Sex/age
(y) Initial symptoms Syndrome MRI
CSF
(cells/protein)
Time of
tumour
diagnosis
Tumour
type Treatments Status
15 M/66 Mnestic deficit,
aphasia
Limbic
encephalitis
MRI: abnormal
(atrophy, Gd2),
brain biopsy:
encephalitis
CSF: abnormal
(0/ml, 81 mg/
dl))
3 mo after
neurological
disease at
orchiectomy
Testicular
germ cell
tumour
Orchiectomy/
steroids/plasma
exchange
Died due to
neurological
deterioration,
tumour: NED
16 M/33 Ophthalmoplegia,
dysarthrophonia,
depressive mood
Limbic
encephalitis,
cerebellar
syndrome
MRI: abnormal
(basal ganglia,
Gd2)
CSF: not done 1.5 y after
neurological
disease
Extragonadal
germ cell
tumour
Surgery,
chemotherapy/
steroids
Tumour: NED at
4 y, neuro: partial
improvement
17 M/38 Obsessive
compulsive
symptoms
Limbic
encephalitis
MRI: abnormal
(hippocampus,
Gd2)
CSF: abnormal
(2/ml, 46 mg/dl,
Ma1 positive)
6 mo after
neurological
disease
Testicular
germ cell
tumour
Orchiectomy, surgery
of metastases,
chemotherapy/
steroids, intravenous
immunoglobulin,
anticonvulsants
Tumour: NED 1 y,
neuro: stable
18 M/21 Epileptic seizure,
amnestic
syndrome
Limbic
encephalitis
MRI: abnormal
(hippocampus,
hypothalamus, Gd?)
CSF: abnormal
(32/ml, 65 mg/
dl)
1 mo before
neurological
disease
Testicular
teratoma
Orchiectomy,
anticonvulsants,
intravenous
immunoglobulin
Tumour: NED,
neuro: stable
19 M/53 Hypaesthesia,
paraesthesia, gait
difficulties,
autonomous
dysregulation
Polyneuropathy MRI: normal, nerve
biopsy: chronic
inflammatory PNP
CSF: abnormal
(normal, 61 mg/
dl)
14 y before
neurological
disease
Testicular
germ cell
tumour
Orchiectomy,
radiotherapy,
chemotherapy,
steroids
Tumour: NED,
neuro: slowly
progressive, follow-
up
20 M/37 Temporal lobe
epilepsy with
aura
Limbic
encephalitis
MRI: abnormal
(temporal lobe,
Gd+), brain biopsy:
encephalitis
CSF: abnormal
(9/ml, 35 mg/dl)
Suspected
tumour 6 mo
before
neurological
disease
Reversible
testicular
swelling
Steroids,
anticonvulsants
Tumour: NED,
neuro: partial
improvement
21 M/70 Gait difficulties Upper + lower
motor neuron
syndrome
MRI: not performed CSF: abnormal
(0/ml, 52 mg/dl)
None None None Neuro: stable,
follow-up
22 M/74 Dementia,
sleepiness
Limbic
encephalitis
MRI: abnormal
(atrophy, Gd2)
CSF: abnormal
(7/ml, 52 mg/dl)
None None None Died due to
neurological
deterioration,
tumour: NED
Gd+, gadolinium uptake; NED, No evidence of disease; PNP, polyneuropathy.
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pneumonia with no autopsy performed. In three patients (3/14,
21%), there was suspicion of a tumour but no definite diagnosis
during the average follow-up period of 2 years. In patient No 3,
a hypermetabolic area highly suspicious for lung cancer was not
reproducible 3 months later. In patient No 10, mammography
and FDG-PET indicated neoplastic lesions in the breast and
uterus, but biopsies could not confirm the suspicion. Follow-up
3 months later still showed a minimal uptaking lesion in the
biopsy area of the breast. The patient is currently closely being
followed. In two patients (2/14, 14%), there has not been
evidence of a tumour to date; in patient Nos 12 and 13, serial
tumour screenings, including FDG-PET, have so far been
negative. Patient No 14 was lost to follow-up. An example of
a suspicious FDG-PET-CT lesion is shown in fig 4.
In four patients the tumour diagnosis was before (mean
4.75 years, median 2 years, range 1–14 years), and in five after
the onset of neurological symptoms (mean 8 months, median
13 months, range 2–14 months). The mean time of close follow-
up for those patients who are alive without evidence of tumour is
4 years (median 23 months, range 12 months to 10 years).
Treatment and outcome
In 11/13 patients (85%, one lost to follow-up), the neurological
disease was progressive. Immunotherapy (steroids, plasma
exchange, intravenous immunoglobulins) had no effect or
achieved only very little or temporary stabilisation of the
neurological syndrome. Patient No 9 improved neurologically
after surgery of her breast cancer. In one case (patient No 3) the
neurological disease stabilised without any immune treatment and
the suspicious pulmonal PET lesion has reversed. Tumour disease
stabilised in seven patients and was progressive in two cases. Five
patients have died (36%), three as a result of neurological
deterioration, one because of chemotherapy complications and
one related to tumour cachexy and worsening of general condition.
Anti-Ta positive patients
Eight patients were positive for anti-Ta (anti-PNMA2 only) and
all were men (table 2). Six patients (6/8, 75%) presented with a
limbic syndrome, one with predominant obsessive–compulsive
symptoms, as reported previously.14 One of those showed
additional brainstem/cerebellar symptoms. One patient devel-
oped a polyneuropathy, another patient signs of upper and
lower motor neuron involvement. Cerebral MRI was performed
in seven patients, with an abnormal result in 6/7—namely,
signal changes in 5/7 and atrophic changes in 1/7. CSF analysis
was abnormal in 7/8 patients (in one case, no lumbar puncture
was performed) with elevated protein (6/7), pleocytosis (3/7)
and positive oligoclonal bands (3/7).
A brain biopsy was performed in two patients. Patient No 15
showed reactive gliosis, activated microglia and a slightly
increased cell density. Patient No 20 had perivascular lympho-
cytic infiltrates, predominantly of CD45 positive T cells and
polyclonal plasma cells confirming the diagnosis of an encepha-
litis rather than the initially suspected primary CNS lymphoma.
Associated tumours
In 5/8 (63%) cases, a germ cell tumour was identified during
follow-up; one had extragonadal manifestations and one was
diagnosed only at orchiectomy. In three of the five patients
with a diagnosed tumour, the tumour was identified only after
the onset of the neurological syndrome (mean time interval of
9 months (median 6), range 3–18 months). In two patients the
tumour was diagnosed before the PNS evolved; one patient
(patient No 18) developed PNS only 1 month after diagnosis of
a testicular teratoma and the other patient (patient No 19) had
a past history of testicular seminoma 14 years previously, and
during 38 months of follow-up ultrasound examination of the
testis detected a heterogeneous non-cystic structure. Open
biopsy revealed macro- and microscopic unremarkable results.
Orchiectomy was considered but was rejected because of the
indolent clinical picture and the patient is under close follow-
up. Patient No 20 recognised a testicular swelling 6 months
before the onset of neurological symptoms, which resolved
spontaneously before the planned biopsy. Close follow-up has
not detected a testicular tumour until now. In patient No 21, no
clinical signs of tumour were present during the 4 years of
follow-up, but the patient refuses any further investigations as
Figure 1 Patient No 2 with anti-Ma associated paraneoplastic limbic
encephalitis. Fluid attenuated inversion recovery sequence of MRI
showing bilateral mesial–temporal lobe signal change. See fig 3 for
biopsy results.
Figure 2 Patient No 13 with anti-Ma associated paraneoplastic
cerebellar syndrome and limbic encephalitis. MRI showing cerebellar
atrophy, predominantly in both hemispheres.
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his condition is stable. Patient No 22 deteriorated rapidly and
died as a result of neurological complications without evidence
of tumour, despite many investigations. A postmortem exam-
ination was not conducted.
Treatment and outcome
Two patients died as a result of neurological deterioration with no
clinical evidence of tumour recurrence in one and no tumour
diagnosis in the other (autopsy not performed). In the six patients
who are still alive, tumour disease remains stable (4/6), whereas
the neurological disease is either slowly progressive (1/6), stable (3/
6) or has even partially improved (2/6). Treatment of the
paraneoplastic syndrome with steroids, plasma exchange or
intravenous immune globulin led to neurological stabilisation in
four cases. In two cases, neurological stabilisation occurred after
curative surgery and additional chemotherapy of the germ cell
tumour. One patient developed neurological symptoms after
orchiectomy, and treatment with intravenous immune globulin
accomplished stabilisation in a moderate condition. In one patient
repetitive courses of high dose steroids resolved distinct unilateral
limbic encephalitis, with residual hippocampal atrophy (fig 5).
Differences between anti-Ta and anti-Ma associated PNS
The data confirm the distinction between anti-Ma and anti-Ta
associated paraneoplastic syndromes. Most relevant differences
are found in sex, age, associated tumour types, neurological
outcome and prognosis. Table 3 includes all previously
published data and emphasises the clinical relevance of the
distinction between anti-Ma and anti-Ta reactivities. Table 4
(see appendix online) summarises the patients according to
antibody status.
DISCUSSION
We have presented a series of 22 newly diagnosed patients with
anti-Ma or anti-Ta reactivity and reviewed all published
patients to date. Our data confirm that patients with anti-Ta
antibodies are usually men of younger age, present with limbic
encephalitis and are likely to have a testicular germ cell tumour
which responds well to treatment with stabilisation of the
neurological syndrome and long term survival.4–7 19 In contrast,
patients with anti-Ma antibodies can be of either sex, usually
middle aged and suffer from a range of tumours and
neurological presentations and do much less well following
tumour treatment.6 Our observations extend the range of anti-
Ma and anti-Ta associated clinical characteristics. If in a man
with anti-Ta no testicular germ cell tumour is found, it is
important to look at extragonadal sites before considering
orchiectomy.4 5 19 20 Anti-Ma associated tumours are more
heterogeneous, and a thorough and repeated tumour search is
mandatory.
Figure 3 Patient No 2 with anti-Ma associated paraneoplastic limbic encephalitis. Brain biopsy. (A) Haematoxylin–eosin staining (6200)
demonstrates diffuse inflammatory lymphocytic infiltrates and reactive astrocytes (arrows). (B, C) Immunocytochemistry stainings (6200) with avidin–
biotin technique show brown labelled immunopositive cells. The perivascular and diffuse parenchymal lymphocytic infiltrates consist of CD3 positive T
cells (B) as well as C79a positive B cells (C).
Figure 4 [18F]Fluorodeoxyglucose positron emission tomography (FDG-PET)/CT examination of patient No 4 with anti-Ma associated paraneoplastic
limbic/thalamic encephalitis. Suspicious mediastinal FDG uptake (B) and inconclusive CT scan with slight wall thickening (A). Fused PET/CT image (C)
locates the PET finding in the oesophagus. Biopsy proved metastatic oesophageal carcinoma.
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Neurologically, the range of presentation of limbic affection
may include an obsessive–compulsive behaviour or bithalamic
involvement mimicking Wernicke encephalopathy.
Furthermore, four of our patients suggest for the first time
that involvement of the peripheral nervous system may also be
associated with anti-Ma or anti-Ta reactivity. Involvement of
the peripheral nervous system would also be theoretically
conceivable as the PNMA proteins are also expressed in
peripheral neurons.1 2 21 In two patients with anti-Ta, affection
of the peripheral nervous system occurred as an isolated
neurological syndrome. In one patient the history of a
seminoma and exclusion of other risk factors was very
suggestive of a paraneoplastic aetiology of the polyneuro-
pathy. The second patient showed clinical and electrophysiolo-
gical involvement of the upper motor neurons in addition
to predominant motor involvement of the peripheral nerves.
This case and another published case17 demonstrate that,
rarely, anti-Ta associated paraneoplastic disease should be
included in the differential diagnosis of motor neuron disease.
As described for other paraneoplastic syndromes, we also
described the first patient with anti-Ma overlapping
with another reactivity (anti-Hu with lung cancer). In this
patient, the polyneuropathy may be ascribed to the anti-Hu
syndrome.
Regarding the high clinical relevance, it is mandatory to check
for cross reactivity and to measure paraneoplastic antibodies
using two different methods as western blots using prokaryotic
proteins might not detect all antibodies present in a polyclonal
patient serum.20
As demonstrated by several of our patients, tumour diagnosis
may be difficult even in definite paraneoplastic syndromes,
probably due to an effective immunological anti-tumour
reaction. Whole body FDG-PET is an important addition to
our diagnostic armentarium.22 Even with a positive FDG-PET, a
Figure 5 Patient No 20 with anti-Ta associated paraneoplastic limbic encephalitis. (A) Signal change in the right mesial temporal lobe. (B) Progressive
lesion with gadolinium uptake 3 months later. (C) Resolution after repeated courses of high dose steroids with residual scar tissue.
Table 3 Summary of all published patients with anti-Ma and anti-Ta associated paraneoplastic syndromes
Anti-Ma (anti-PNMA1 + PNMA2) Anti-Ta (anti-PNMA2) Statistical analysis
n 26 36
Sex (F/M) 16/10 8/28 p = 0.004 (FT)
Age (y) (mean, median, range) 61, 61, 38–82 44, 38, 21–81 p = 0.001 (RST)
Neurological syndromes Cerebellar/brainstem syndrome 77%,
limbic encephalitis 65%,
polyneuropathy 12%, extrapyramidal
symptoms 8%, myelopathy 4%
Limbic encephalitis 64%,
cerebellar/brainstem syndrome
39%, extrapyramidal symptoms
6%, polyneuropathy 6%,
myelopathy 3%
NS
Tumour Tumour diagnosis in 77%, thereof lung
25%, GIT 15%, breast 10%, NHL 10%,
germ cell 10%, salivary gland 10%,
renal rhabdoid 5%, ovary 5%,
melanoma 5%, unknown primary 5%
Tumour diagnosis in 89%, thereof
germ cell 75%, lung 9%, breast
9%, NHL 3%, ovary 3%
Germ cell vs non-
germ cell p,0.001
(FT)
Time of diagnosis of tumour Paraneoplastic syndrome before
tumour diagnosis: 66%, range 2–
14 mo, paraneoplastic syndrome after
tumour diagnosis: 39%, range 4 mo–
14 y
Paraneoplastic syndrome before
tumour diagnosis: 82%, range 2–
36 mo, paraneoplastic syndrome
after tumour diagnosis: 18%,
range 1 mo–14 y
NS
CNS imaging Abnormal 86% Abnormal 82% NS
CSF Abnormal 77% Abnormal 81% NS
Outcome (neuro) Progression 75%, stabilisation 19%,
improvement 5%
Progression 31%, stabilisation
38%, improvement 31%
Progression vs non-
progression
p = 0.009 (FT)
Outcome (tumour) Stabilisation 82%, progression 27% Stabilisation 95%, progression: 5% NS
Death 38% (thereof 70% due to neurological
deterioration)
14% (thereof 80% due to
neurological deterioration)
Death vs alive
p = 0.021 (FT)
FT, Fisher’s exact test; GIT, gastrointestinal; NHL, non-Hodgkin lymphoma; RST, Mann–Whitney rank sum test.
Classification of anti-Ma and anti-Ta according to the respective publication. In some studies testing of anti-PNMA1 was not
performed and hence classification as anti-Ta or anti-Ma unclear.
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first attempt to diagnose the tumour histologically may be
negative but can be positive at follow-up biopsy if the FDG-PET
hypermetabolism persists, as demonstrated by one of our
patients (patient No 4). An exception of clinical relevance is
testis tissue, as the utilisation of FDG-PET is of limited
sensitivity because of a hypermetabolic background.
Furthermore, in anti-Ta, tumour diagnosis may only be
obtained after radical orchiectomy, a procedure that must be
weighed against the clinical background.19 Furthermore, tumour
diagnosis may be delayed by several years, and close follow-up
for patients with a paraneoplastic antibody is essential.
Tumour diagnosis may also be hampered by possible
regression of the tumour by the underlying immune response.3
A probable clue to the immunopathology of paraneoplastic
neurological disease (PND) is provided by patient No 20 with a
reversible suspicious testicular swelling and patient No 15 with
a diagnosis of intratubular germ cell neoplasia at orchiectomy
only. As has been hypothesised before,21 23 the immune response
in the testis is triggered at an early stage or limited stage of
cancer and an early and effective immunological response at the
tumour site only becomes evident with the evolving neurolo-
gical symptoms, but can accomplish tumour regression.
Not all of the patients were found to have tumours and some
of the tumours were not those typically associated with Ma
antibodies. However, all patients fitted the criteria for definite
paraneoplastic syndromes, as defined by Graus and colleagues.3
One way to establish whether the associated tumours were
immunological related to the syndromes would be to look for
the Ma antigens in the tumours. Unfortunately, biopsy material
was not available for any of the patients with atypical tumours.
Our neuropathology findings show that in the rare cases
when a brain biopsy is performed for differential diagnosis a
paraneoplastic encephalitis may be mistaken for a cerebral
lymphoma. In this situation, re-evaluation of the histology by
an expert neuropathologist is necessary. In addition to the
presence of anti-Ma/anti-Ta antibodies, neuropathological
analysis of the clonality of lymphoid cells may demonstrate
polyclonality and points towards encephalitis.24–26
As has been reported previously, immunosuppressive treat-
ment, such as intravenous immunoglobulin and plasma
exchange, had little effect on outcome except in a few cases.
This might be for two reasons: the neuronal damage takes place
subacutely and is irreversible. Any immunosuppressive treat-
ment must therefore take place as early as possible, probably
best within the first month after onset of neurological
symptoms.27 Furthermore, numerous pieces of evidence indicate
that the tumour response and PND is characterised by the
presence of PNS antigen specific T cells, which are triggered by
the capture of apoptotic tumour cells by tissue dendritic
cells.4 5 7 8 10 12–14 16 After migration to lymph nodes and the
presence of CD4+ helper T cells, CD8+ killer T cells are
activated. The above mentioned therapies work well in
antibody mediated diseases, such as Lambert–Eaton myasthenic
syndrome, but fail in PNS with an immune mechanism with
predominantly cell mediated effects and probably less pathoge-
netic effect of the detected antibodies.10 15 16
In conclusion, anti-Ma and anti-Ta reactivities are of high
clinical relevance in patients presenting with subacute brain-
stem or limbic symptoms and, if present, a thorough and
persistent tumour search is warranted. Furthermore, it has to be
kept in mind that every patient might present with unique
clinical symptoms and that with the growing number of
patients, new clinical presentations of tumour associations may
be reported in the future.
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